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Abstract
Glucocorticoid excess increases fat mass, preferentially within
omental depots; yet circulating cortisol concentrations are
normal in most patients with metabolic syndrome (MS). At a
pre-receptor level, 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) activates cortisol from cortisone locally within
adipose tissue, and inhibition of 11b-HSD1 in liver and
adipose tissue has been proposed as a novel therapy to treat
MS by reducing hepatic glucose output and adiposity. Using a
transformed human subcutaneous preadipocyte cell line
(Chub-S7) and human primary preadipocytes, we have
defined the role of glucocorticoids and 11b-HSD1 in
regulating adipose tissue differentiation. Human cells were
differentiated with 1.0 mM cortisol (F), or cortisone (E) with
or without 100 nM of a highly selective 11b-HSD1 inhibitor
PF-877423. 11b-HSD1 mRNA expression increased across
adipocyte differentiation (P!0.001, nZ4), which was
paralleled by an increase in 11b-HSD1 oxo-reductase activity
(from nil on day 0 to 5.9G1.9 pmol/mg per h on day 16,
P!0.01, nZ7). Cortisone enhanced adipocyte differen-
tiation; fatty acid-binding protein 4 expression increased 312-
fold (P!0.001) and glycerol-3-phosphate dehydrogenase
47-fold (P!0.001) versus controls. This was abolished by
co-incubation with PF-877423. In addition, cellular lipid
content decreased significantly. These findings were
confirmed in the primary cultures of human subcutaneous
preadipocytes. The increase in 11b-HSD1 mRNA expression
and activity is essential for the induction of human
adipogenesis. Blocking adipogenesis with a novel and specific
11b-HSD1 inhibitor may represent a novel approach to treat
obesity in patients with MS.
Journal of Endocrinology (2008) 197, 297–307
Introduction
Glucocorticoid excess (Cushing’s syndrome) causes visceral
obesity, insulin resistance, diabetes mellitus, dyslipidaemia,
hypertension and premature vascular mortality; as such it
represents an excellent paradigm for patients with themetabolic
syndrome (MS). However, Cushing’s syndrome is rare and
circulating glucocorticoid levels are usually normal or even
slightly reduced in obese patients (Fraser et al. 1999). At a cellular
level, glucocorticoids within human adipose tissue, specifically
in omental depots, can be generated from inactive circulating
cortisone (in humans) or 11-dehydrocorticosterone (in rodents)
through the oxo-reductase activity of 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1; Bujalska et al. 1997b).
Transgenic mice with adipose tissue-targeted 11b-HSD1
overexpression develop visceral obesity, insulin resistance,
hyperlipidaemia and hypertension without altering circulating
glucocorticoids (Masuzaki et al. 2001, 2003), while mice with
11b-HSD1 overexpression in the liver develop MS without
obesity (Paterson et al. 2004). Conversely, global deletion of
11b-HSD1 caused reduced visceral fat accumulation and
improved insulin sensitivity on a high fat diet (Kotelevtsev
et al. 1997, Morton et al. 2004). At a molecular level,
glucocorticoids exert potent effects upon adipose tissue; in
mature rat adipocytes, dexamethasone decreases glucose uptake
and oxidation (Olefsky 1975, De et al. 1981). Glucocorticoids
increase lipolysis by up-regulating the expression of the rate-
limiting enzyme hormone-sensitive lipase (Slavin et al. 1994), as
well as lipogenic enzyme, lipoprotein lipase (Yang et al. 1993). In
preadipocytes, glucocorticoids are essential for terminal
adipogenesis (Hauner et al. 1987) and limit cell proliferation
(Tomlinson et al. 2002).Theprocess of cellular differentiation is a
highly synchronized cascade of regulated differentiation-
dependent gene expression. Genes such as retinoblastoma
proteins that regulate the cell cycle (Richon et al. 1997)
are followed by adipogenic transcription factors, such as
peroxisome proliferator-activated receptor g (PPARg) and
CCAAT enhancer-binding protein (Rosen & MacDougald
2006). Mature adipocytes express late differentiation genes
involved in lipid metabolism and lipid transport including
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glycerol-3-phosphate dehydrogenase (G3PD) and fatty acid-
binding protein 4 (FABP4; Hotamisligil et al. 1996); many of
these genes are regulated by glucocorticoids (Wu et al. 1996,
Rosen & MacDougald 2006). Previously, we have shown that
non-selective inhibition of 11b-HSD1 can prevent human
adipocyte differentiation in vitro (Bujalska et al. 1999). The
potential for therapeutic intervention has been tested in rodent
models where selective 11b-HSD1 inhibitors lower plasma
glucose, improve insulin sensitivity and in some studies reduce
body weight in mice (Alberts et al. 2002, Kershaw et al. 2005).
However, the potency of these inhibitors has been variable and
there are no data on efficacy in human tissue. We report the
development of a selective inhibitor against human 11b-HSD1,
PF-877423 (Pfizer Global R&D, La Jolla, CA, USA) and the
effect of this compound upon adipogenesis in a well-
characterised differentiating human subcutaneous preadipocyte
cell line (Darimont et al. 2003, Qiao et al. 2005) and in primary
cultures of subcutaneous human preadipocytes.
Research design and methods
Recombinant protein assay
Wild-type recombinant human 11b-HSD1 protein (24–292)
was used for studying the inhibitor kinetics. Radio-labelled
[1,2-3H]-cortisone was purchased from American Radio-
labeled Chemicals Inc (St Louis, MO, USA). NAD (reduced
form; NADPH), glucose-6-phosphate (G6P) and G6P
dehydrogenase (G6PD) were purchased from Sigma–
Aldrich. All the concentrations reported in the following
section are final in the assay buffer. In addition, the enzyme
concentrations represent the active concentrations that were
determined by active-site titration using a tight-binding
inhibitor. The experimental data were fitted by using the
non-linear regression analysis software, Grafit (Leather-
barrow (2001) GraFit Version 5, Erithacus Software Ltd,
Horley, UK).
The measurement of the in vitro 11b-HSD1 activity was
performed in a 100 mM triethanolamine buffer (pH 8.0),
containing 200 mM NaCl, 0.02% n-dodecyl b-D-maltoside,
5% glycerol and 5 mM b-mercaptoethanol. A typical
reaction for the determination of enzyme activity comprised
the following: 5 nM enzyme pre-incubated for at least
30 minutes in the assay buffer in the presence of 500 mM
NADPH in round-bottom 96-well plates (Costar cat #
3365). Next, the reaction was initiated by adding a
regenerating system (consisting of 2 mM G6P, 1 U/ml
G6PD and 6 mM MgCl2) and labelled
3H-cortisone as
substrate. After an incubation period (30–40 min), 100 ml
of the assay mixture were transferred to a second empty
round-bottom 96-well plate and mixed with an equal
volume of dimethylsulphoxide (DMSO) to quench the
reaction. Then, a 15 ml aliquot of the assay solution was
loaded into a C-18 column (Polaris C18-A, 50!4. 6 mm,
5 u, 180 A˚, Varian; Polaris, Palo Alto, CA, USA connected
to an automated High-Throughput Liquid Chromatography
instrument (Cohesive Technologies, HTLC, Franklin, MA,
USA). The radioactive material from the column was
detected with a b-RAM model 3 Radio-HPLC detector
(IN/US, Tampa, FL, USA). Substrate and product peaks
were separated by using an isocratic mixture of 38:62
methanol to water (v/v) at a flow rate of 1. 0 ml/min. Under
these experimental conditions, the retention time for
cortisone and cortisol were 4.5 and 5.5 min respectively.
The initial reaction velocities recorded were in the linear
range and were determined by measuring the peak area for
cortisol formation with time.
Recombinant protein kinetic analysis
The inhibition of 11b-HSD1 by PF-877423 was analysed
by fitting to the equation described below (Equation
(1); Morrison 1969) and provided an accurate measure-
ment for the value of Kiapp at a fixed concentration of
cortisone
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where [E]o and [I]o are the active enzyme and inhibitor
concentration respectively; Vi and Vo are the rates of
cortisone reduction in the presence or in the absence of
inhibitor respectively. Four Kiapp values were determined
by varying the cortisone concentration while keeping
the concentration of NADPH constant at 500 mM in
the assay buffer. The true inhibition constant, Ki, for
PF-877423 was then obtained by plotting the Kiapp
values versus the cortisone concentration, [C]o, and
fitting the data using Equation (2) for a competitive
inhibitor
KiappZKi 1C
½Co
Km
 
(2)
where Km was the Michaelis–Menten constant for
cortisone.
HEK293 and Chubb-S7 cell culture
HEK293 cells stably transfected with human 11b-HSD1
(HEK293T1) or 11b-HSD2 (HEK293T2) cDNA as
described previously (Bujalska et al. 1997a) were used to
study the specificity of inhibitor PF-877423 upon 11b-HSDs.
Cells were cultured in minimum essential medium (MEM)
media supplemented with 10% fetal bovine serum (FBS) and
1% non-essential fatty acids; for experiments, cells were
seeded into 24-well tissue culture dishes and maintained in
MEM with 10% FBS until confluence.
The Chub-S7 cell line was derived from human subcu-
taneous adipose tissue (Darimont et al. 2003) by co-expressionof
human telomerase reverse transcriptase and papillomavirus E7
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oncoprotein (HPV-E7) genes. The cell line has an unlimited life
span and the capacity to accumulate lipid without chromosomal
alteration. Confluent Chub-S7 cells were cultured in 75 cm2
TC flasks in DMEM/Ham’s F-12 medium supplemented
with 10% FBS. For experiments, cells were seeded in 24-well
plates at density 105 cells/well. Chub-S7 were differentiated (up
to 21 days) according to Hauner et al. (1987) with 166 nM
human insulin (I-9278 Sigma), 1 mM PPARg agonist
(GW1929, Camlab, Cambridge, UK) and, where specified,
with the addition of 1 mM cortisol (F). For inhibition studies,
Chub-S7 cells were differentiated with 0.5 mM cortisone (E)
and an optimised concentration of the selective 11b-HSD1
inhibitor, PF-877423, at a final concentration of 100 nM.
Human subcutaneous stromal-vascular cell differentiation
Confluent human subcutaneous stromal-vascular (s–v) cells
(96-well plates) were obtained from Zen-Bio Inc. (Research
Triangle Park, NC, USA) and allowed to recover overnight at
37 8C 5% CO2. The following day, day 0, differentiation was
initiated by incubating cells in differentiating media, DM2(E)
(Zen-Bio Inc.), which consists of DMEM/Ham’s F-12
medium containing FBS, L-glutamine, penicillin/streptomy-
cin, insulin, indomethacin, 3-isobutyl-1-methylxanthine
with 1 mM E and vehicle (DMSO not exceeding 0.1%). To
define the effect of the PF-877423 inhibitor upon the
differentiation of primary preadipocytes, cultures were
supplemented with 300 nM PF-877423 (in DMSO). Control
cells cultured without E. Media were replenished and
PF-877423 or vehicle treatment repeated every 2–3 days,
except when 11b-HSD1 activity was assessed.
Measuring lipid content in human subcutaneous s–v cells
Lipogenesis in human subcutaneous s–v cells was measured as
triglyceride accumulation. Cells were carefully washed with
PBS and lysed in situ by adding 50 ml/well of Hecameg (10%
solution inwater –Calbiochem,Nottingham,UK).After gentle
shaking at room temperature for 10 min, 200 ml triglyceride
(Infinity) reagent (Thermo DMA, Louisville, CO, USA) was
added to each well. Plates were read after 10–20 min at
500 nm with correction at 660 nm (Spectra MAX PLUS –
Molecular Devices Corporation, Sunnyvale, CA, USA).
Results were expressed as optical density (OD) values.
HEK293 and Chubb-S7 11b-HSD assay
Cells were washed and incubated with 100 nM F (for
dehydrogenase activity) or E (for oxo-reductase activity) with
appropriate tritiated tracer – 3HF (Du Pont, Stevenage, UK) or
3H E (0.02 mCi/reaction; Bujalska et al. 1999). PF-877423
specificity upon11b-HSD1was carried outwith the additionof
100 nM inhibitor to HEK293T1 and HEK293T2 cells 24 h
before and during the enzyme assay. After 3 h incubation with
substrate, media was removed and steroids extracted with 4 ml
dichloromethane, evaporated under the air and reconstituted
with 70 ml dichloromethane, then spotted on silica plates
(Sigma–Aldrich). Steroidswere separated by thin-layer chroma-
tography in chloroform and ethanol (92:8) and steroid
conversion was quantified using a LabLogic AR-200 scanner
(LabLogic, Sheffield, UK). Cells were washed and protein
concentration was measured using colorimetric 96-well plate
assay (Bio-Rad) and total RNAwas extracted.
Human subcutaneous s–v cells 11b-HSD1 assay
During 11b-HSD1 activity assessment in human subcutaneous
s–v cells, the medium was changed to basal medium (BM-1,
Zen-Bio Inc.) containingonlyantibiotics, and cellswere cultured
for 24 h in the presence of PF-877423 with or without 0.5 mM
E. At the end of the incubation, the cortisol signal was
quantitatively determined in the 100 ml cell supernatant with
the Correlate-Enzyme Immunoassay Cortisol kit (Assay Designs
Inc. Ann Arbor, MI, USA) following the manufacturers’
instructions. Plates were read on a plate reader (Spectra MAX
PLUS – Molecular Devices Corporation) at 405 nm, with
correction at 580 nm. Activity has been expressed as cortisol
production in pg/ml per 24 h.
Total RNA extraction and RT reaction
Total RNA was extracted from cells using TriReagent
(Sigma) according to the manufacturer’s protocol. Integrity
and concentration of RNA were assessed by electrophoresis
and spectrophotometry respectively. Reverse transcription
was carried out using AMVand random primers at 37 8C for
1 h. All RT reagents were purchased from Promega.
PCR
Expression studies were carried out using gene specific primers
for human 11 b-HSD1, hexose 6-phosphate dehydrogenase
(H6PDH), glucocorticoid receptor a (GRa, FABP4), G3PD,
glucose transporter 4 (GLUT-4) and PPARg. All primers were
designed using primer 3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3.cgi) and their sequences from 50 to 30 are
shown in Table 1. Primers for 18S as internal control were
purchased from Ambion (Quantum RNATM Classic 18S
Internal Standard #1716; Ambion). PCRs were carried out at
95 8C for 30 s, 60 8C for 30 s and 72 8C for 30 s in 20 ml final
volume for 30 cycles.
Real-time PCR
Quantitative mRNA expression levels of 11b-HSD1, H6PDH,
GRa, FABP4,G3PD,GLUT-4 andPPARg2weremeasured by
real-time PCR using an ABI 7500 system (Perkin–Elmer,
Biosystems, Warrington, UK). PCR was performed in 25 ml
reactions on 96-well plates. Reactions contained TaqMan
universal PCR master mix (Applied Biosystems, Foster City,
CA, USA), 900 nmol primers, 100–200 nmol TaqMan probe
and25–50 ngcDNA.All reactionswere correlated to expression
11b-HSD1 is essential for human adipogenesis . I J BUJALSKA and others 299
www.endocrinology-journals.org Journal of Endocrinology (2008) 197, 297–307
of ribosomal 18S rRNA (provided as a pre-optimized mix;
Perkin–Elmer) as an internal reference. All target gene probes
were labelled with the fluorescent label FAM and the 18S probe
with the fluorescent label VIC.Reactionswere as follows: 50 8C
for 2 min, 95 8C for 10 min, and then 40 cycles of 95 8C for 15 s
and 60 8C for 1 min. Data were analysed according to the
manufacturer’s guidelines and were obtained as Ct values (the
cycle number at which logarithmic PCR plots cross a calculated
threshold line) andused to determine dCt values (dCtZCt of the
target geneminusCt of the internal reference, 18S). Primers and
probes for 11b-HSD1,H6PDHandG3PDwere designed using
PrimerExpress 1.0 software (Applied Biosystems). Sequences
from 50 to 30 are shown in Table 2. Expression assay kits were
purchased from Applied Biosystems to measure the gene
expression of GRa, GLUT-4, PPARg2 and FABP4.
Statistical analysis
Where datawere normally distributed, unpaired Student’s t-test
was used to compare single treatmentswith control. If normality
tests failed, then non-parametric tests were used. One-way
ANOVA on ranks was used to compare multiple treatments
(SigmaStat 3.1, Systat Software Inc., Point Richmond, CA,
USA). Results were expressed as mean valuesGS.D. or S.E.M.
values and a P value of !0.05 was accepted as statistically
significant. Statistical analysis on real-time PCR data was
performed on mean DCt values and not on fold changes.
Results
Kinetics of PF-877423 upon recombinant 11b-HSD1 protein
The potency for PF-877423 was strongly affected by the
presence of the substrate in the assay buffer (Fig. 1): K
app
i
values increased at high cortisone concentration, suggesting
that the inhibitor behaved as a reversible and competitive
inhibitor against cortisone. Fitting the experimental data
using equation (2) provided a value of 0.2G0.04 and 333.4G
109.2 nM for the inhibition constant, Ki, and the apparent
Michaelis–Menten constant, Km respectively.
Specificity of PF-877423
11b-HSD enzyme assays on HEK293T1 and HEK293T2 cells
showed total abolition of dehydrogenase (12.4G1.0 vs 0.2G
0.01, % cortisol to cortisone conversion, meanGS.D.) and oxo-
reductase (34.7G0.6 vs 0.4G0.1, % cortisone to cortisol
conversion, meanGS.D.) activities of 11b-HSD1 following
incubation with 100 nM PF-877423 for 24 h (Fig. 2A), but
PF-877423 had no effect on 11b-HSD2 activity (63.6G4.0 vs
62.2G4.4, % cortisol to cortisone conversion, meanGS.D.,
control versus PF-877423 respectively; Fig. 2B). No toxic
effects ofPF-877423were observedup to10 mMconcentrations
using a commercially available assay kit (CellTiter 96 Aqueous,
Promega; data not shown).
Table 1 Primer sequences for various human genes for the PCR
Forward Reverse
Gene
HSD11B1 ACCAGAGATGCTCCAAGGAA ATGCTTCCATTGCTCTGCTT
H6PDH AGAAGCGAGACAGCTTCCAC GCTGCTGGGAAAAGAACAAC
GRa TCGACCAGTGTTCCAGAGAAC TTTCGGAACCAACGGGAATTG
GLUT-4 GCCATTGTTATCGGCATTCT CTACCCCTGCTGTCTCGAAG
PPARg1 TCTCTCCGTAATGGAAGACC GCATTATGAGACATCCCCAC
PPARg2 GCGATTCCTTCACTGATAC GCATTATGAGACATCCCCAC
G3PD GGAAGACATTGGAGGCAAAA CCACGGCCACTACATTCTTT
FABP4 CATCAGTGTGAATGGGGATG ATGCGAACTTCAGTCCAGGT
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3).
Table 2 Primer and probe sequences for various human genes for the real-time PCR
Forward Reverse Probe
Gene
HSD11B1 AGGAAAGCTCATGGGAGGACTAG ATGGTGAATATCATCATGAA AAAGATTC CATGCTCATTCTCAACCACATCA CCAACA
H6PDH GGGCCTATGGAACCTCCAA GACCCACGTTTCTCACTGAC TCT CCGTGGCGCTACTCATGGACAC A
PPARg2 AGAAGAAGGCGGCGTTGTC TCAGGTTGAGGCCACCATC AGGGGCCACCACAGACTTGCAC AT
G3PD CCATCAGTTCATCGGCAAGAT TCGTCTACCCCCTTAATAAG AGATATG AGGGCCATCTGAAGGCAAACGC C
Primers and probes were designed using PrimerExpress software (Applied Biosystems, UK).
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Characterisation of chub-S7 cells
At confluence (day 0), Chub-S7 cells did not accumulate lipid
droplets (Fig. 3A); however, they readily underwent adipogen-
esis (shown as oil red O staining) when cultured for 21 days in
chemically-defined, serum-free media (166 nM insulin, 1 mM
PPARg agonist and 1 mM F; Fig. 3B). As demonstrated
by conventional PCR, confluent undifferentiated Chub-S7
cells expressed GRa H6PDH and PPARg1 mRNA but not
11b-HSD1, PPARg2, GLUT-4, G3PD or FABP4 mRNA
(Fig. 3C). In the differentiated Chub-S7 cells, increased
expression of adipogenic markers including G3PD and
FABP4 was observed. This process resulted in an increase in
11b-HSD1, GLUT-4 and PPARg2 mRNA levels (Fig. 3D).
Across differentiation, 11b-HSD1 oxo-reductase activity
increased significantly; from nil on day 0 to 0.4G0.2 on day
3, 5.3G0.7 on day 5, 8.4G0.14 on day 7, 10.5G1.9 on day 9
and 5.9G1.9 on day 16 (pmol/mg per h, meanGS.D., nZ7, all
P!0.01 versus previous time point; Fig. 4A). Conventional
PCRfindingswere endorsed and quantified by real-time PCR.
Expression of 11b-HSD1 mRNA increased 2.9-fold on day 5,
3.6-fold on day 7, 3.4-fold on day 9 (P!0.01) and 38.1-fold on
day 16 (P!0.001) when compared with day 3, nZ4 (Fig. 4B).
We observed a transient increase in H6PDH mRNA levels
(11b-HSD1 co-factor provider) – 2.9-fold on day 3, 3.5-fold
on day 5, 3.7-fold on day 7, 3.4-fold on day 9 and 0.6-fold
on day 16 versus day 0, P!0.01 (Fig. 4C) – but there was no
significant change in GRa mRNA during Chub-S7
differentiation (Fig. 4D).
Significant increases in differentiationmarkers FABP4 (2-fold
on day 5 (P!0.01), 38-fold on day 7, 142-fold on day 9 and
870-fold onday 16 versus day 3,P!0.001) andG3PD (4.5-fold
on day 7 (P!0.01), 22-fold on day 9 and 380-fold on day 16
versus day 5, P!0.001) were also observed (Fig. 5A and B
respectively). When compared with day 7, the expression of
adipocyte-specific genes including GLUT-4 and PPARg2 also
increased – 2.1-fold on day 9 and 9.8-fold on day 16, P!0.01
(GLUT-4) and 1.3-fold on day 7 and 2.2-fold on day 16,
P!0.01 (PPARg2; Fig. 5C and D respectively).
Glucocorticoid metabolism and adipogenesis in Chub-S7 cells
incubated with PF-877423
Chub-S7 cells differentiated for 10 days with 500 nM
cortisone showed increased 11b-HSD1 oxo-reductase
activity: 14.6G2.3 (E) versus 3.4G1.3 (control), pmol/mg
per h meanGS.E.M., P!0.001 (Fig. 6A), and mRNA
expression (14.1-fold versus control; Fig. 6B). Co-incubation
with 100 nM PF-877423 abolished this effect: 14.6G2.3 (E)
versus 1.3G1.1 (ECPF-877423) vs 0.6G0.5 (PF-877423)
pmol/mg per h, meanGS.E.M. (Fig. 6A) and 14.1-fold (E)
versus 1.2-fold (ECPF-877423), 11b-HSD1 activity and
mRNA respectively (Fig. 6B). Differentiated Chub-S7 cells
with E showed increased expression of the adipogenic
markers FABP4 (312-fold versus control, P!0.001) and
G3PD (47-fold versus control, P!0.001) – an effect that was
completely abolished by co-incubation with PF-877423 (1.3-
and 0.7-fold, FABP4 and G3PD respectively; Fig. 6C and D).
The change in adipogenesis following incubation with the
11b-HSD1-specific inhibitor was confirmed visually through
staining the cells with oil red O after 21 days of differentiation.
A marked increase in the number of red-stained cells was
observed in cells differentiated with E or F but not in the
presence of PF-877423 (Fig. 6E).
Figure 1 Effect of cortisone concentration upon the apparent
inhibition constant Kiapp of the inhibitor PF-877423: a value for
the true inhibition constant Ki (0.2G0.04 nM) and the Michaelis–
Menten constant Km (333.4G109.2 nM) is calculated by fitting the
experimental data using equation (2).
Figure 2 (A) PF-877423 inhibits 11b-HSD1 enzyme activity
(dehydrogenase: 12.4G1.0 vs 0.2G0.01, % cortisol to cortisone
conversion, and oxo-reductase: 34.7G0.6 vs 0.4G0.1, % cortisone
to cortisol conversion, meanGS.D.) as measured in HEK293T1
(HEK293 cells stably transfected with human 11b-HSD type 1
cDNA), nZ3 but not (B) 11b-HSD2 enzyme activity (63.6G4.0 vs
62.2G4.4, % cortisol to cortisone conversion, meanGS.D., control
versus PF-9Z877423 respectively) as measured in HEK293T2 (cells
stably transfected with human 11b-HSD type 2 cDNA), nZ3.
P values: **P!0.01, ***P!0.001.
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Human subcutaneous s–v cells differentiation
Human subcutaneous s–v cells differentiated with ECPF-
877423 had significantly lower 11b-HSD1 oxo-reductase
activity compared with cells differentiated with E at any time
point studied (day 6: 154G8 vs 5387G182; day 9: 128G1 vs
5489G230; day 14: 174G18 vs 4041G106; day 20: 409G27
vs 10443G78; day 22: 330G7 vs 11218G193 pg/ml per 24 h,
meanGS.D., P!0.001, nZ3, EK or ECPF-877423 treated
respectively (Fig. 7A)). Lipid content in cells differentiated
with E and PF-877423 was significantly lower than in cells
differentiated with E only and similar to undifferentiated cells
(day 16, 0.25G0.03 vs 0.20G0.01; day 20, 0.3G0.02 vs
0.20G0.01; day 22, 0.27G0.01 vs 0.19G0.01; OD (500/
660 nm); meanGS.D., P!0.01, nZ3, EK or ECPF-877423
treated respectively; Fig. 7B).
Discussion
Numerous studies (Hauner et al. 1989,Gregoire et al. 1991,Wolf
1999), including our own (Bujalska et al. 1999, 2002b), have
Figure 3 Oil red O staining in (A) confluent Chub-S7 cells (day 0) and (B) differentiated Chub-S7 (day 21). RT-PCR analysis (30 cycles) of
nine gene expressions in (C) confluent Chub-S7 cells and (D) in differentiated Chub-S7 cells.
Figure 4 (A) 11b-HSD1 oxo-reductase activity (cortisone to cortisol conversion); nil on day 0 to 0.4G0.2 on day 3,
5.3G0.7 on day 5, 8.4G0.14 on day 7, 10.5G1.9 on day 9 and 5.9G1.9 on day 16, pmol/mg per h, meanGS.D. versus
previous time point, nZ7 and mRNA levels measured by real-time PCR of (B) 11b-HSD1 (2.9-fold increase on day 5,
3.6-fold on day 7, 3.4-fold on day 9 and 38.1-fold on day 16 when compared with day 3). (C) H6PDH increased 2.9-
fold on day 3, 3.5-fold on day 5, 3.7-fold on day 7, 3.4-fold on day 9 and 0.6-fold on day 16 versus day 0 and (D) GRa
(no significant change) across Chub-S7 differentiation, nZ4. P values: **P!0.01, ***P!0.001.
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defined the permissive role of GCs in inducing adipocyte
differentiation. Here, we extend those observations to a novel
transformed human adipocyte cell line that should greatly
enhance in vitrohuman-based adipocyte research studies.Within
5 days of incubation in chemically defined media comprising
insulin, PPARg agonist and glucocorticoid, impressive differ-
entiation was observed in Chub-S7 cells as assessed by markers
including FABP4, G3PD and adipocyte-specific genes such as
GLUT-4 and PPARg2. Adipogenesis was an ongoing process
up to 16 days in culture with intracellular lipid stores confirmed
by oil red O staining. No significant changes were observed in
GRa expression during this differentiation phase; earlier studies
had reported increased GR expression in omental versus
subcutaneous adipose tissue and had argued that this may be
the one factor explaining the predilection of glucocorticoids for
visceral obesity (Bronnegard et al. 1990). However, more
recently our array and real-time PCR analyses failed to
demonstrate any difference in GR expression between human
omental and subcutaneous preadipocytes (Bujalska et al. 2006)
and adipose tissue (unpublished data). Together with the data in
this study, it seems unlikely that changes in GR expression per se
are important in the adipogenesis process.
At a pre-receptor level our group has focussed on the role of
11b-HSD1 and the regeneration of cortisol from inactive
cortisone in human adipose tissue. Previously we have
demonstrated increased expression of 11b-HSD1 in omental
compared with subcutaneous depots (Bujalska et al. 1997b), and
importantly a switch in the directionality of enzyme activity
from predominant dehydrogenase to oxo-reductase (Bujalska
et al. 2002a), probably as a result of induction of the NADPH
donor source for 11b-HSD1within the endoplasmic reticulum
(ER) lumen, H6PDH (Ozols 1993). In support of these
observations, in this study, the rise in H6PDH mRNA levels
probably explained the increase in 11b-HSD1-mediated oxo-
reductase activity between days 3 and 9 in addition to an increase
in 11b-HSD1 mRNA levels. Furthermore, decreased H6PDH
mRNAexpression seen onday 16might account for the decline
in 11b-HSD1 oxo-reductase activity despite highmRNA. The
impressive increase in 11b-HSD1 expression across adipocyte
differentiation has been noted recently in mouse 3T3-L1 cells
(Kim et al. 2007), as it has been done in other differentiating cell
systems including osteoblasts (Eijken et al. 2005). In both cases
cells have been incubated with glucocorticoids that themselves
positively regulate 11b-HSD1 (Bujalska et al. 1997b); it is not
possible from these or previous data sets to conclude whether or
not the increased 11b-HSD1 expression is glucocorticoid
mediated or a manifestation of the differentiation process per se.
Nevertheless, 11b-HSD1 expression, resulting in a function-
ally active oxo-reductase,was clearly linked to the differentiation
phenotype. Incubation of Chub-S7 cells with inactive steroid,
cortisone, induced a degree of adipocyte differentiation similar
to that observed with cortisol. This could be explained on the
basis of 11b-HSD1-mediated oxo-reductase activity with a Km
for cortisone in Chubb-S7 cells of 100 nM which is similar to
the reports in other 11b-HSD1-expressing cell systems
(Monder & Lakshmi 1989, Ricketts et al. 1998) including
studies on the recombinant enzyme (KmZ333 nM;Walker et al.
2001, Shafqat et al. 2003). Evaluation of the competitive
11b-HSD1 inhibitor, PF-877423, indicated selectivity for
the type 1 11b-HSD isoform with a Ki£0.2 nM in the
recombinant assay and IC50w5 nM in Chubb-S7 cells.
Selectivity of the inhibitor towards 11b-HSD1 isoform but not
11b-HSD2 is crucial as patients with impairment in the latter
are presented with severe hypertension, (White et al. 1997).
Figure 5 Gene expression analysed by real-time PCR of adipogenic markers; (A) FABP4: (log scale) 2-fold increase on day 5,
38-fold on day 7, 142-fold on day 9 and 870-fold on day 16 versus day 3; (B) G3PD: 4.5-fold on day 7, 22-fold on day 9 and
380-fold on day 16 versus day 5; (C) PPARg2: 1.3-fold on day 9 and 2.2-fold on day 16 versus day 7; and (D) GLUT-4: 2.1-fold
on day 9 and 9.8-fold on day 16 versus day 7 across Chub-S7 cell differentiation. P values: **P!0.01, ***P!0.001.
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PF-877423 selectivity was undertaken using a transformed
cell line expressing human 11b-HSD2 enzyme where no
inhibitory effect was observed. Incubation of cells with 100 nM
PF-877423 completely abolished the cortisone induction of
FABP4, G3PDH and 11b-HSD1 itself in Chubb-S7 cells. We
also demonstrated that the transformed cell line data were
consistent with data in primary human subcutaneous pre-
adipocytes. While incubation with cortisone yielded a less
impressive effect on adipogenesis in human subcutaneous
preadipocytes when compared with Chubb-S7 cells (this
might reflect a more advanced adipogenic lineage of primary
cultures), inhibition of 11b-HSD1 activity nevertheless reduced
the ability of human subcutaneous preadipocytes to differentiate
and accumulate lipid.
Whilst the cell line that we have used is subcutaneous in
origin and the expression of 11b-HSD1 is higher in omental
human preadipocytes (Bujalska et al. 1997b) and therefore we
predict that the impact upon omental cells would be more
pronounced. We anticipate that this would not lead to
preferential loss of subcutaneous fat. Unfortunately, omental
cell lines are not available for study and in vivo human clinical
studies have not been performed.
Previously, non-selective 11b-HSD inhibitors have been
shown to diminish human adipocyte differentiation in vitro
(Bujalska et al. 1999) and increase insulin sensitivity in man
(Walker et al. 1995), but a lack of isozyme selectivity can cause
water retention and hypertension. Since then, patents have been
filed on compounds that report to be selective 11b-HSD1
inhibitors. An aryl sulphonamide derivative has been shown to
reduce insulin levels and improve glucose tolerance when
administered to rodents for 7 days (Alberts et al. 2002). Similar
data have been reported for an adamantyl triazole that also
reduced body weight and the progression of atherosclerosis in
mice (Hermanowski-Vosatka et al. 2005). Transgenic mouse
models have established 11b-HSD1 as a novel therapeutic target
in this regard; global deletion of 11b-HSD1 results in improved
Figure 6 Chub-S7 cells differentiated with 0. 5 mM E and with or without the selective 11b-HSD1 inhibitor PF-877423 at 100 nM. All
experiments were carried out on differentiated cells on day 10, nZ3. (A) 11b-HSD1 oxo-reductase activity (cortisone to cortisol
conversion): 14.6G2.4 (E) versus 1.2G1.1 (ECPF-877423) vs 3.4G1.3 (control), pmol/mg per h meanGS.E.M., P!0.001, (B) 11b-HSD1
mRNA expression and adipogenic markers (C) FABP4, (D) G3PD (log scale, P!0.001 and P!0.001 respectively) and (E) Chub-S7 cells
differentiated for 21 days and stained with oil red O; 1) control: 166 nM insulin, PPARg agonist, 100 nM PF-877423, 2) 0.5 mM E,
3) 0.5 mM EC100 nM PF-877423 and 4) positive control (differentiation with 0.5 mM F). P values: **P!0.01, ***P!0.001.
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glucose tolerance through reduced gluconeogenesis and hepatic
glucose output (Kotelevtsev et al. 1997, Morton et al. 2001),
while targeted overexpression of 11b-HSD1 in adipose tissue
recapitulates features of the MS including central adiposity
(Masuzaki et al. 2001). In the liver of db/db mice (a model of
type 2 diabetes), GR and 11b-HSD1 mRNA expression
positively correlated with blood insulin and glucose (Liu et al.
2005). Inhibition of GR and 11b-HSD1 expression either with
GRantagonist (RU486; Liu et al. 2005) or by chronic activation
of liver X receptor (Liu et al. 2006) attenuated the phenotype of
type 2 diabetes in mice.
In humans, the situation is less clear with regard to a role for
11b-HSD1 in the pathogenesis of MS. Some authors have
argued for a primary overexpression of 11b-HSD1 in affected
patients akin to that observed in some animal models
(Paulmyer-Lacroix et al. 2002, Rask et al. 2002). However,
while the expression of 11b-HSD1 might be increased, at least
in subcutaneous adipose tissue in obese patients with MS and
type 2 diabetes (Tomlinson et al. 2002, Alberti et al. 2007), no
such increase was observed in omental adipose tissue.
Furthermore, based on urinary cortisol/cortisone metabolite
ratios and plasma cortisol generation curves following oral
cortisone acetate that primarily reflects hepatic 11b-HSD1
expression, a reduction, not an increase, in 11b-HSD1
expression was observed at least in subjects with simple obesity
(Stewart et al. 1999, Tomlinson et al. 2004).We have argued that
obesity is not primarily a state of 11b-HSD1overexpression, but
that the fall in hepatic 11b-HSD1activitywith increased visceral
adipositymight serve as a protectivemechanism to offset hepatic
glucose output and further adiposity (Valsamakis et al. 2004).
Failure of such a switch off in 11b-HSD1 expression might be a
factor that determines the onset and persistence of hypergly-
caemia in obese patients with type 2 diabetes mellitus
(Valsamakis et al. 2004). Further studies are indicated to define
the exact role of 11b-HSD1 in the pathophysiology of human
MS. Irrespective of the outcome of these studies, selective
inhibitors such as PF-877423 offer a real advance in the
prevention and treatment of diabetes in subjects with obesity
with the potential added benefit of inhibiting adipocyte
differentiation. A reduction in adipogenesis specifically within
omental depots is likely to further improve the metabolic
phenotype of these patients. Clinical studies characterising a
novel, potent (Ki 0.2 nM) and fully selective 11b-HSD1
inhibitor preventing lipogenesis in vitro will further our
understanding of the role of local glucocorticoid metabolism
in human adipose tissue.
Acknowledgements
The work was supported by a Wellcome Trust Programme
Grant (Ref No 066357) and MRC Grant (G0502165). The
authors thank Jeff Zhu for providing the human 11b-HSD1
recombinant protein.
Disclosure
I J B, L L G, J W Tand C D declare no conflict of interest. J E,
A N F and P A R are employed by Pfizer. P M S is on the
advisory board for Pfizer Global R&D.
References
Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G & Invitti
C 2007 Type 2 diabetes and metabolic syndrome are associated with
increased expression of 11b-hydroxysteroid dehydrogenase 1 in obese
subjects. International Journal of Obesity 31 1826–1831.
Figure 7 (A) Effect of chronic exposure to the selective 11b-HSD1 inhibitor PF-877423 on subcutaneous s–v cells. 11
b-HSD1 enzyme inhibition by 300 nM PF-877423 measured as the production of cortisol (day 6: 154G8 vs 5387G182;
day 9: 128G1 vs 5489G230; day 14: 174G18 vs 4041G106; day 20: 409G27 vs 10443G78; day 22: 330G7 vs
11218G193 pg/ml per 24 h, meanGS.D., P!0.001, nZ3, EK or ECPF-877423-treated respectively). (B) Inhibition of
lipid accumulation by 300 nM PF-877423 in subcutaneous stromal–vascular cells (day 16: 0.25G0.03 vs 0.20G0.01;
day 20: 0.3G0.02 vs 0.20G0.01; day 22: 0.27G0.01 vs 0.19G0.01; OD (500/660 nm), nZ3, EK or
ECPF-877423-treated respectively), P values: **P!0.01, ***P!0.001.
11b-HSD1 is essential for human adipogenesis . I J BUJALSKA and others 305
www.endocrinology-journals.org Journal of Endocrinology (2008) 197, 297–307
Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C,
Ronquist-Nii Y, Ohman B & Abrahmsen L 2002 Selective inhibition of
11b-hydroxysteroid dehydrogenase type 1 decreases blood glucose
concentrations in hyperglycaemic mice. Diabetologia 45 1528–1532.
Bronnegard M, Arner P, Hellstrom L, Akner G & Gustafsson JA 1990
Glucocorticoid receptor messenger ribonucleic acid in different regions of
human adipose tissue. Endocrinology 127 1689–1696.
Bujalska I, Shimojo M, Howie A & Stewart PM 1997a Human 11b-
hydroxysteroid dehydrogenase: studies on the stably transfected isoforms
and localization of the type 2 isozyme within renal tissue. Steroids 62 77–82.
Bujalska IJ, Kumar S & Stewart PM 1997b Does central obesity reflect
‘Cushing’s disease of the omentum’? Lancet 349 1210–1213.
Bujalska IJ, Kumar S, Hewison M & Stewart PM 1999 Differentiation of
adipose stromal cells: the roles of glucocorticoids and 11b-hydroxysteroid
dehydrogenase. Endocrinology 140 3188–3196.
Bujalska IJ, Walker EA, Hewison M & Stewart PM 2002a A switch in
dehydrogenase to reductase activity of 11b-hydroxysteroid dehydrogenase
type 1 upon differentiation of human omental adipose stromal cells.
Journal of Clinical Endocrinology and Metabolism 87 1205–1210.
Bujalska IJ, Walker EA, Tomlinson JW, Hewison M & Stewart PM 2002b
11b-hydroxysteroid dehydrogenase type 1 in differentiating omental human
preadipocytes: from de-activation to generation of cortisol. Endocrine
Research 28 449–461.
Bujalska IJ, Quinkler M, Tomlinson JW, Montague CT, Smith DM &
Stewart PM 2006 Expression profiling of 11b-hydroxysteroid
dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous
and omental human preadipocytes. Journal of Molecular Endocrinology 37
327–340.
Darimont C, Zbinden I, Avanti O, Leone-Vautravers P, Giusti V, Burckhardt P,
Pfeifer AM &Mace K 2003 Reconstitution of telomerase activity combined
with HPV-E7 expression allow human preadipocytes to preserve their
differentiation capacity after immortalization. Cell Death and Differentiation
10 1025–1031.
De PR, Green A, Kao MY & Olefsky JM 1981 Effects of prednisolone and
dexamethasone in vivo and in vitro: studies of insulin binding, deoxyglucose
uptake and glucose oxidation in rat adipocytes. Diabetologia 21 149–153.
Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM,
Uitterlinden AG, Pols HA & van Leeuwen JP 2005 11b-Hydroxysteroid
dehydrogenase expression and glucocorticoid synthesis are directed by a
molecular switch during osteoblast differentiation. Molecular Endocrinology
19 621–631.
Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E & Connell JM
1999 Cortisol effects on body mass, blood pressure, and cholesterol in the
general population. Hypertension 33 1364–1368.
Gregoire F, Genart C, Hauser N &Remacle C 1991 Glucocorticoids induce a
drastic inhibition of proliferation and stimulate differentiation of adult rat fat
cell precursors. Experimental Cell Research 196 270–278.
Hauner H, Schmid P & Pfeiffer EF 1987 Glucocorticoids and insulin promote
the differentiation of human adipocyte precursor cells into fat cells. Journal of
Clinical Endocrinology and Metabolism 64 832–835.
Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R &
Pfeiffer EF 1989 Promoting effect of glucocorticoids on the differentiation
of human adipocyte precursor cells cultured in a chemically defined
medium. Journal of Clinical Investigation 84 1663–1670.
Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez
M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS et al. 2005
11b-HSD1 inhibition ameliorates metabolic syndrome and prevents
progression of atherosclerosis in mice. Journal of Experimental Medicine
202 517–527.
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE &
Spiegelman BM 1996 Uncoupling of obesity from insulin resistance
through a targeted mutation in aP2, the adipocyte fatty acid binding
protein. Science 274 1377–1379.
Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR & Flier JS 2005
Adipocyte-specific glucocorticoid inactivation protects against diet-
induced obesity. Diabetes 54 1023–1031.
Kim J, Temple KA, Jones SA, Meredith KN, Basko JL & Brady MJ 2007
Differential modulation of 3T3-L1 adipogenesis mediated by 11b-
hydroxysteroid dehydrogenase-1 levels. Journal of Biological Chemistry
282 11038–11046.
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P,
Best R, Brown R, Edwards CR, Seckl JR et al. 1997 11b-Hydroxysteroid
dehydrogenase type 1 knockout mice show attenuated glucocorticoid-
inducible responses and resist hyperglycemia on obesity or stress. PNAS
94 14924–14929.
Liu Y, Nakagawa Y, Wang Y, Sakurai R, Tripathi PV, Lutfy K & Friedman TC
2005 Increased glucocorticoid receptor and 11b-hydroxysteroid dehydro-
genase type 1 expression in hepatocytes may contribute to the phenotype of
type 2 diabetes in db/db mice. Diabetes 54 32–40.
LiuY,YanC,WangY,NakagawaY,NerioN,AnghelA,LutfyK&FriedmanTC
2006LiverX receptor agonist T0901317 inhibition of glucocorticoid receptor
expression in hepatocytes may contribute to the amelioration of diabetic
syndrome in db/db mice. Endocrinology 147 5061–5068.
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR &
Flier JS 2001 A transgenic model of visceral obesity and the metabolic
syndrome. Science 294 2166–2170.
MasuzakiH,YamamotoH,KenyonCJ, Elmquist JK,MortonNM,Paterson JM,
Shinyama H, Sharp MG, Fleming S, Mullins JJ et al. 2003 Transgenic
amplification of glucocorticoid action in adipose tissue causes high blood
pressure in mice. Journal of Clinical Investigation 112 83–90.
Monder C & Lakshmi V 1989 Evidence for kinetically distinct forms of
corticosteroid 11b-dehydrogenase in rat liver microsomes. Journal of Steroid
Biochemistry 32 77–83.
Morrison JF 1969 Kinetics of the reversible inhibition of enzyme-catalysed
reactions by tight-binding inhibitors.Biochimica et Biophysica Acta 185 269–286.
Morton NM, HolmesMC, Fievet C, Staels B, Tailleux A,Mullins JJ & Seckl JR
2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and
glucose tolerance in 11b-hydroxysteroid dehydrogenase type 1 null mice.
Journal of Biological Chemistry 276 41293–41300.
Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C,
Walker BR, Flier JS, Mullins JJ & Seckl JR 2004 Novel adipose tissue-
mediated resistance to diet-induced visceral obesity in 11b-hydroxysteroid
dehydrogenase type 1-deficient mice. Diabetes 53 931–938.
Olefsky JM 1975 Effect of dexamethasone on insulin binding, glucose
transport, and glucose oxidation of isolated rat adipocytes. Journal of Clinical
Investigation 56 1499–1508.
Ozols J 1993 Isolation and the complete amino acid sequence of lumenal
endoplasmic reticulum glucose-6-phosphate dehydrogenase. PNAS
90 5302–5306.
Paterson JM,MortonNM,FievetC,KenyonCJ,HolmesMC, Staels B, Seckl JR
& Mullins JJ 2004 Metabolic syndrome without obesity: hepatic over-
expression of 11b-hydroxysteroid dehydrogenase type 1 in transgenic mice.
PNAS 101 7088–7093.
Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC & Grino M 2002
Expression of the mRNA coding for 11b-hydroxysteroid dehydrogenase
type 1 in adipose tissue from obese patients: an in situ hybridization study.
Journal of Clinical Endocrinology and Metabolism 87 2701–2705.
Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M,
Friedman JE & Shao J 2005 C/EBPalpha regulates human adiponectin gene
transcription through an intronic enhancer. Diabetes 54 1744–1754.
Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O,
Andrew R & Olsson T 2002 Tissue-specific changes in peripheral cortisol
metabolism in obese women: increased adipose 11b-hydroxysteroid
dehydrogenase type 1 activity. Journal of Clinical Endocrinology and Metabolism
87 3330–3336.
Richon VM, Lyle RE &McGehee RE, Jr 1997 Regulation and expression of
retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte
differentiation. Journal of Biological Chemistry 272 10117–10124.
Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC & Stewart PM
1998 Regulation of 11b-hydroxysteroid dehydrogenase type 1 in primary
cultures of rat and human hepatocytes. Journal of Endocrinology 156 159–168.
Rosen ED &MacDougald OA 2006 Adipocyte differentiation from the inside
out. Nature Reviews. Molecular Cell Biology 7 885–896.
I J BUJALSKA and others . 11b-HSD1 is essential for human adipogenesis306
Journal of Endocrinology (2008) 197, 297–307 www.endocrinology-journals.org
Shafqat N, Elleby B, Svensson S, Shafqat J, Jornvall H, Abrahmsen L &
Oppermann U 2003 Comparative enzymology of 11b -hydroxysteroid
dehydrogenase type 1 from glucocorticoid resistant (guinea pig) versus
sensitive (human) species. Journal of Biological Chemistry 278 2030–2035.
Slavin BG, Ong JM & Kern PA 1994 Hormonal regulation of hormone-
sensitive lipase activity and mRNA levels in isolated rat adipocytes. Journal of
Lipid Research 35 1535–1541.
Stewart PM, Boulton A, Kumar S, Clark PM& Shackleton CH 1999 Cortisol
metabolism in human obesity: impaired cortisone/cortisol conversion in
subjects with central adiposity. Journal of Clinical Endocrinology and Metabolism
84 1022–1027.
Tomlinson JW, Sinha B, Bujalska I, Hewison M & Stewart PM 2002
Expression of 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue is
not increased in human obesity. Journal of Clinical Endocrinology and
Metabolism 87 5630–5635.
Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L & Stewart PM
2004 Weight loss increases 11b-hydroxysteroid dehydrogenase type 1
expression in human adipose tissue. Journal of Clinical Endocrinology and
Metabolism 89 2711–2716.
Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG,
Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH et al. 2004
11b-hydroxysteroid dehydrogenase type 1 activity in lean and obese males
with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism
89 4755–4761.
Walker BR, Connacher AA, Lindsay RM, Webb DJ & Edwards CR 1995
Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for
11-oxosteroid reductase in enhancing glucocorticoid receptor activation.
Journal of Clinical Endocrinology and Metabolism 80 3155–3159.
Walker EA, Clark AM, Hewison M, Ride JP & Stewart PM 2001 Functional
expression, characterization, and purification of the catalytic domain of
human 11b-hydroxysteroid dehydrogenase type 1. Journal of Biological
Chemistry 276 21343–21350.
White PC, Mune T & Agarwal AK 1997 11b-Hydroxysteroid dehydrogenase
and the syndrome of apparent mineralocorticoid excess. Endocrine Reviews
18 135–156.
Wolf G 1999 The molecular mechanism of the stimulation of adipocyte
differentiation by a glucocorticoid. Nutrition Reviews 57 324–326.
Wu Z, Bucher NL & Farmer SR 1996 Induction of peroxisome proliferator-
activated receptor gamma during the conversion of 3T3 fibroblasts into
adipocytes is mediated by C/EBPb, C/EBPd, and glucocorticoids.
Molecular and Cellular Biology 16 4128–4136.
Yang S, Xu X & Bjorntorp P 1993 Effects of dexamethasone on primarily
cultured newly differentiated rat adipocytes from different adipose tissue
regions. Obesity Research 1 99–105.
Received in final form 26 February 2008
Accepted 4 March 2008
Made available online as an Accepted Preprint
4 March 2008
11b-HSD1 is essential for human adipogenesis . I J BUJALSKA and others 307
www.endocrinology-journals.org Journal of Endocrinology (2008) 197, 297–307
